Diffusion Pharmaceuticals (DFFN) Receives a Rating Update from a Top Analyst
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Diffusion Pharmaceuticals (DFFN). The company’s shares closed last Friday at $1.02.
According to TipRanks.com, Ramakanth is a top 100 analyst with an average return of 42.8% and a 55.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Cellectar Biosciences, Trillium Therapeutics, and Harpoon Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Diffusion Pharmaceuticals.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.85 and a one-year low of $0.28. Currently, Diffusion Pharmaceuticals has an average volume of 8.18M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.